Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online 
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
CHICAGO, April 11, 2016 -- The Female Health Company (NASDAQ:FHCO) (FHC or the Company) today announced the creation of a new abstract entitled "FC2 Dual Protection, Non-Hormonal, Latex Free Female Condom" and authored by Brooke Faught, MSN, WHNP-BC; Irwin Goldstein, MD; Mark Martens, MD; Kelli Rodriguez; and Lisa Levin.
On February 25, 2016, the abstract was presented at the International Society for the Study of Women’s Sexual Health (ISSWSH) 2016 Annual Meeting in Charleston, South Carolina. The study surveyed women (ages 25-64) regarding their use of the FC2 Female Condom. Results of the survey indicated a very high percentage (82%) would recommend FC2 to others, and the same percentage (82%) stated positive ease of use. The abstract will also be presented at the Academy of Women’s Health’s “Women's Health 2016: The 24th Annual Congress” taking place from April 14 to April 17, 2016 in Washington, DC.
About The Female Health Company
The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2). Since the Company began distributing FC2 in 2007, the product has been shipped to 144 countries. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover key aspects of FC2, including its overall design and manufacturing process. The FC2 Female Condom® is the only currently available female-controlled product approved by FDA that offers dual protection against sexually transmitted infections, including HIV/AIDS, the Zika virus, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.
For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to [email protected].
Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123
